Evicenter
MarkdownMedical informationP&T meetings
VK2735

Chronic weight management

Last updated
184 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Place in treatment, anticipated use, and care setting

9 evidence topics · 8 sources

Summary: anticipated place in treatment

VK2735 is investigational and has no approved indication. Guidelines place anti-obesity pharmacotherapy as an adjunct to lifestyle intervention: the AGA strongly recommends pharmacotherapy in addition to lifestyle intervention for adults with BMI of 30 or higher, or 27 or higher with weight-related complications, who have an inadequate response to lifestyle interventions, and the ADA names semaglutide or tirzepatide as the preferred agents for people with diabetes and overweight or obesity. The WHO guideline describes obesity as requiring “lifelong care”. The OMA and ACOFP describe family physicians as “often the first line of treatment”, and ICER expects that “much of the treatment of obesity, including prescribing medications, will be done by primary care clinicians”. Viking describes the subcutaneous formulation as suited to weight maintenance with every-other-week or monthly dosing after weekly induction, and the VANQUISH-1 extension will include these less-frequent regimens, with results anticipated in 2028. Viking describes the oral tablet as positioned to become the first oral dual GLP-1/GIP agonist to reach the market and expects many initial users of oral therapies to transition to subcutaneous administration. In a May 2024 national poll, 12% of U.S. adults reported ever taking a GLP-1 agonist and 6% reported current use.